Masimo Corp is a global medical technology company that specializes in non-invasive monitoring solutions for patients
The company is best known for its innovative pulse oximetry technology, which measures blood oxygen levels and vital signs in real-time, providing healthcare professionals with critical data to enhance patient care. Masimo's products are designed to improve patient outcomes and safety across a wide range of clinical settings, including hospitals, outpatient facilities, and home care environments. In addition, the company develops advanced monitoring devices and software that integrate with existing medical systems, thereby optimizing workflows and enhancing the overall efficiency of healthcare delivery.
These large-cap stocks were top performers last week. Heico, Xpeng, Li Auto, Lineage, Erie Indemnity, Lloyds, Unum, FICO, Masimo, Smith & Nephew, AB InBev, and Nutanix all saw significant gains.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQDXCM).
Shares of medical tech company Masimo (NASDAQMASI)
jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS expectations. Sales grew 9% year on year, fueled by broad based demand. In addition, its full-year EPS guidance outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a solid quarter.
Medical tech company Masimo (NASDAQMASI) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.4% year on year to $600.7 million. Its non-GAAP profit of $1.80 per share was 26.3% above analysts’ consensus estimates.
The mid-cap-centric S&P 400 index has rallied 21.4% year-to-date. Within the mid-cap space, a handful of stocks have the potential to become large-caps in 2025. Here's why they may be worth consideration.
